Summary There is evidence to suggest that glutathione (GSH) and glutathione-S-transferases (GST) complete response (CR, n =18), partial response (PR, n = 10) or who had static disease (SD, n = 7) or progressive disease (PD, n =4) respectively. There was no relationship between GSH concentration and response (ANOVA, P = 0.32). There were also no relationship between GST isoenzyme expression and response (P Fisher's exact test 0.51-0.55 and chi-squared test 0.98-0.99). In conclusion, there was no association between the concentration of GSH or expression of GST isoenzymes and response to single agent carboplatin in primary previously untreated EOC.
Single agent carboplatin therapy after primary surgery has been standard treatment in the Northern Region (UK) for patients with advanced epithelial ovarian cancer (EOC stages Ic-IV). A meta-analysis indicates that 56% of patients with advanced ovarian cancer will respond to single agent carboplatin as first-line therapy, suggesting that the remainder have tumours which are intrinsically resistant (Rozencwig et al., 1990) . Of the patients who do respond to first-line carboplatin, some 60% will subsequently relapse and hence acquired resistance is also a significant problem. Resistance to platinum complexes is multifactorial and includes: decreased accumulation of drug, increased intracellular detoxification, which can involve glutathione (GSH), glutathione S-transferases (GSTs) and metallothioneins, increased DNA repair and increased tolerance of unrepaired DNA damage. Notably, several mechanisms may operate concomitantly (De Graeff et al., 1988) . Furthermore, essentially all of the data on resistance to platinum compounds are derived from cell lines or experimental animal systems, and it is uncertain whether the mechanisms defined in these model systems are relevant to the clinical setting.
Of all the mechanisms implicated in preclinical studies, GSH and its metabolism is the one most commonly identified in resistance to cisplatin and carboplatin. GSH is tripeptide, gamma-glutamylcysteinylglycine, and is the most abundant non-protein thiol found in the cell. GSH is present in millimolar concentrations and is found throughout the cell, with the bulk in the cytoplasm; subcellular particles,. such as the nucleus and mitochondria, having smaller amounts . GSH plays a role in the detoxification and repair of cell injury induced by a wide range of toxic agents which include cytotoxic drugs, radiation and hyperthermia . GSH functions primarily through nucleophilic thioether formation and peroxidation/reduction reactions. The exact mechanism by which GSH decreases platinum complex cytotoxicity is not well established; but the following possibilities have been proposed (reviewed by De Graeff et al., 1988) : alteration of platinum complex transport, drug inactivation through the formation of an inactive GSH -Pt complex, decreased binding of platinum to DNA and increased DNA repair. More recently data have been published which indicate that cisplatin may be extruded from cells as a glutathione conjugate, and that increased expression of the GS-X pump may be associated with drug resistance (Ishikawa and AliOsman, 1993; .
The cytosolic GSTs are a multigene family of enzymes that exist as homo-and hetero-dimers each of which have a molecular weight of between 21 and 28 kDa Gulick and Fahl, 1995) . Four different classes of enzyme have been described, a, p, ir and 0 which differ in immunoreactivity. Monomers of one class will not dimerise with those of another. Within each class there may be several different isoforms which share amino acid homology but may differ significantly in substrate specificity. GSTs have been shown to detoxify a wide range of xenobiotics (reviewed by Ciaccio and Tew, 1993) , including cytotoxic drugs, through both the catalysis of glutathione conjugate formation (Hall et al., 1994a; and by sequestration .
Although there is evidence from studies of both cell lines and clinical material that increased expression of GSTs and raised levels of GSH may be associated with resistance to cytotoxic drugs, the relationship between response and expression in patients remains unclear. The aim of this study was to relate response to single-agent carboplatin to tumour levels of GSH and GST in EOC. Sample preparation for GSH measurements Tumour tissue was removed from storage in liquid nitrogen and cut while frozen into two sections. The first section was weighed wet and then dried in a heating block at 50°C until the weight was stable. The dry weight was recorded and the wet weight to dry weight ratio was calculated. The second tissue section was ground in liquid nitrogen using a pestle and mortar. Once ground, the fragments were collected into a cooled Teflon-glass homogeniser and homogenised in 25 volumes of 6.5% (w/v) TCA. Three 450 ,ul samples of the homogenate were removed. An aliquot of 50 ,l 0.5 mM GSH was added to the first of these aliquots and 50 ,l 1.0 mM GSH to the second. An addition 50 MI of 6.5% (w/v) TCA was added to the third aliquot. After adding the GSH solutions, the samples were mixed and centrifuged (10 000 g, 12 min, 4C) using a Biofuge 15 (Heraeus Sepatech, Germany). An aliquot of 75 ,il of 1 M potassium hydrogen phosphate was mixed with 75 jl of the supernatant, 150 ,ul of monobromobimane (mBrB) reagent was added (see below) and, after gentle mixing, the sample incubated at room temperature for 5 min in the dark. The reaction was stopped with 15 ,ul of 100% (w/v) TCA and the samples were kept at -80°C until analysed by HPLC within 2 weeks of preparation.
High performance liquid chromatography measurement of GSH in tumour samples The method used was based upon the use of mBrB and is a modification of the one described by Cotgreave and Moldeus (1986) . This method results in the maximal recovery of both free and low molecular weight thiols from the tissue and, by virtue of the HPLC separation used, gives specific detection of GSH.
Monobromobimane reagent and standard curve preparation The reagent used was 8 mM monobromobimane (Calbiochem, Nottingham, UK) in 50 mM N-ethylmorpholine (NEM). To prepare 25 ml of the mBrB reagent, 158 pl NEM was added to 23 ml deionised water in a 30 ml glass tube. MBrB (54.25 mg) was thoroughly dissolved in a minimum amount of acetonitrile, the solutions of NEM and mBrB were then mixed, and pH adjusted to 8.0, using 1 M hydrochloric acid, and then made up to 25 ml in a volumetric flask with deionised water.
For preparation of the GSH standard curve, eight different standard solutions were prepared (2.5, 5, 10, 20, 40, 60, 80 and 100 /iM of GSH). GSH (64.53 mg) was dissolved in 50 ml of phosphate-buffered saline (PBS), giving a concentration of 4 mM GSH. A 0.25 ml aliquot of the solution was diluted up to 10 ml in a volumetric flask, giving a total concentration of 100 ,iM of GSH which was diluted serially to give the concentrations indicated above. Fifty ,l of 30 mM dithiothreitol (DTT), made up fresh every day in PBS, was added to 1 ml of each of the above standard solutions and the standards were then left for 30 min at room temperature. of GSH during processing compensated for. Figure 1 shows the result for the method of addition in one patient sample. The GSH concentration is given by the extrapolated x-axis intercept. The recovery is given by the slope of the line which was fitted by unweighed linear regression analysis (r2>0.99 in all cases). When possible (18 patients) more than one sample (2-5) was collected from different locations within the tumour. After measurement of GSH concentration in each sample separately, the mean value for all of the samples was used as the GSH concentration value for the patient, unless there was wide variation (>2-fold), in which case the patient was considered inevaluable for GSH determination. The original GSH content of the tumour tissue was expressed per gram of tissue dry weight.
Immunohistochemical detection of glutathione-S-transferase expression
The glutathione S-transferase (GST) isoenzyme distribution was determined using three rabbit polyclonal antibodies raised against the human 7t, a and ,u forms of the enzyme . The use of polyclonal antibodies to detect different GST isoenzymes has been described previously Harrison et al., 1989; . The principles of the methods of immunohistochemical staining have been described by , and for GST assessment in particular, by Randall et al. (1990) .
Paraffin wax sections (4 gm thickness) were cut from the tissue blocks and mounted on slides. The sections were dried, dewaxed and rehydrated. After washing with water, the sections were washed in Tris-buffered saline (TBS) (150 mM sodium chloride, 5 mM Tris, pH 7.9 with 1 M hydrochloric acid). The excess TBS was wiped and the sections were incubated in normal swine serum (NSS) (Dako, High Wycombe, Bucks, UK) for 10 min. The excess NSS was removed and the primary anti-GST antibody was added at a dilution of 1:400 in NSS. After overnight incubation at 4°C the sections were rinsed with TBS. The excess TBS was wiped and the sections were incubated in biotinylated anti-rabbit secondary antibody (Dako) at a dilution of 1:20 in TBS. Following incubation for 30 min at room temperature, the sections were washed with TBS and then incubated in streptavidin-biotin horseradish peroxidase (Dako) (1:200 in NSS) solution for 30 min. The sections were washed and immersed in TBS for 5 min. After wiping the slides, the peroxidase reaction was developed using 3,3',-diaminobenzidine tetrahydrochloride solution (DAB) for 10 min (80 mg DAB in 100 ml TBS containing 0.086 mg imidazole). The sections were washed with distilled water and treated with copper sulphate enhancer for 1 min, thoroughly washed in water and counter-stained with haematoxylin and mounted.
Tumour slides were stained in batches (10-12 each). In each batch, and to control the quality of the staining, positive control slides were added to the batch (breast tumour for 7t, kidney for a and positive liver control for y GSTs; supplied by Novocastra Laboratories Ltd, Newcastle-upon-Tyne, UK).
Scoring was performed jointly (JPS and SGA) and the tissue sections selected for evaluation were those that only contained malignant changes as determined by an experi- Figure 3 and a one-way analysis of the variance did not show any significant relationship between GSH concentration and response (ANOVA, P=0.32).
Tumour GST isoenzyme expression and its relationship to response to carboplatin GST isoenzyme expression was assessed by immunohistochemistry using polyclonal antibodies on fixed tumour samples from the same 39 patients whose tumours were analysed for GSH content. For each isoenzyme, the intensity of the staining and the percentage of tumour cells stained was recorded. For the purpose of this study, and in analysing the results in relation to response, patients were divided into two groups: responders (complete and partial) and non-responders (static or progressive disease); GST isoenzyme expression was defined as positive if the staining intensity was strong and more than 10% of the tumour cells stained positive. Most of the tumour samples (34/39) had positive expression of GST, while only two different tumours expressed oa or GST. (Rozencwieg et al., 1990) .
In numerous preclinical studies (Godwin et al., 1992; Hamilton et al., 1985; Saburi et al., 1989 ) GSH and GSTs have been implicated as important factors in intrinsic and acquired resistance to platinum compounds. Furthermore, a number of clinical studies have been reported which linked increased expression of GSTs with resistance to cytotoxic drugs in a variety of tumours including colorectal and lung cancer , in which expression of the it isoform was implicated, and acute lymphoblastic leukaemia (Hall et al., 1994b) in which expression of, class GST was associated with an increased probability of relapse. However, it should be noted that several other mechanisms of resistance have also been suggested from preclinical work, including altered metallothionen content, increased DNA repair and reduced cellular accumulation, and the relative contribution of these various parameters to clinical resistance is currently unclear.
In the clinical setting, Green et al. (1993) studied GST expression in benign and malignant ovarian tumours and, in agreement with the present study, found that it GST was the most prevalent, being present in the majority of the malignant epithelia and 83% of the non-malignant tissue. There was no significant difference in the overall distribution of positive staining for i, a or p in the malignant and nonmalignant biopsies, although the intensity of staining was greater in malignant epithelia. There was no significant association between survival and the presence or absence of a or it GST subtypes, but the patients who showed resistance to chemotherapy (oral chlorambucil, single-agent cisplatin or a combination of cisplatin and cyclophosphamide), as opposed to responding patients, were found to have higher staining intensity for X GST (a Kruskal-Wallis test applied to the data for tumour response against staining intensity gave a Pvalue of 0.003).
Van der Zee (1992) studied GST activity and isoenzyme expression in benign ovarian tumours, untreated malignant ovarian tumours and malignant ovarian tumours after platinum -cyclophosphamide chemotherapy. In untreated malignant tumours GST activity and i GST expression were not related to histological type, differentiation grade or tumour volume index. GST isoenzyme patterns were identical in benign tumours and in malignant tumours, both before and after platinum-cyclophosphamide chemotherapy, with i GST again being the predominant isoform. As in the study reported here, no role for GSTs as a predictor of response and hence a drug resistance mechanism was suggested. A similar finding was reported by , who studied GST activity and isoenzyme expression in human ovarian cancer tumours both before and after cytotoxic chemotherapy. Again, there was no statistically significant difference between GST activity or isoenzyme distribution in the two groups of patients. These authors observed that GST activities in both pre-chemotherapy and post-chemotherapy tumours were significantly higher than GST activity in normal ovaries. Also, a isoenzyme expression was higher in the normal ovary than in tumour tissue. In the work of (1992) , cytotoxic chemotherapy consisted of five different regimes of drugs with a small number of patients in each group, which prevented an analysis of the relationship between GST expression and response to therapy.
In conclusion, the results presented in this study show that there was no significant relationship between GSH concentration or GST isoenzyme expression and response to singleagent carboplatin chemotherapy in EOC. These data do not support the hypothesis that GSH content or GST isoenzyme expression are major determinants of sensitivity to carboplatin chemotherapy in primary ovarian cancer. It is important to stress the point that this study only looked at the role of GSH/GSTs in intrinsic resistance. The possibility still exists that when resistance develops subsequent to chemotherapy (acquired resistance), GSH/GSTs may play an important
